

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number  
**WO 02/055684 A2**


- (51) International Patent Classification<sup>7</sup>: **C12N 9/00**
- (21) International Application Number: PCT/US02/00438
- (22) International Filing Date: 9 January 2002 (09.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/757,824 9 January 2001 (09.01.2001) US
- (71) Applicant (*for all designated States except US*): **UNIVERSITY OF IOWA RESEARCH FOUNDATION** [US/US]; Oakdale Research Campus, 100 Oakdale Campus #214 TIC, Iowa City, IA 52242-5000 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DAVIDSON, Beverly, L.** [US/US]; 3640 Johnston Way, N.E., North Liberty, IA 52242 (US). **MAO, Qinwen** [CN/US]; 1264 Shannon Drive, Iowa City, IA 52246 (US). **XIA, Haibin** [CN/US]; 1264 Shannon Drive, Iowa City, IA 52246 (US).
- (74) Agent: **VIKSINS, Ann, S.**; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).
- (81) Designated States (*national*): AF, AG, AI., AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PTD-MODIFIED PROTEINS



(57) Abstract: The present invention provides polynucleotides and expression vectors containing a sequence encoding a soluble lysosomal enzyme and a sequence encoding Tat protein transduction domain (PTD), and the corresponding polypeptides. The present demonstrates the utility of these protein fusions in altering the bioavailability of proteins for use in treating genetic diseases or acquired diseases. The invention further provides cell expression systems, and methods of treating a genetic disease or cancer in a mammal using the polynucleotides, polypeptides, or expression system of the present invention.

WO 02/055684 A2

## PTD-MODIFIED PROTEINS

5            Portions of the present invention were made with support of the United States Government via a grant from the National Institutes of Health under grant numbers HD33531 and NS34568. The U.S. Government therefore may have certain rights in the invention.

10 Background of the Invention

Gene transfer is now widely recognized as a powerful tool for analysis of biological events and disease processes at both the cellular and molecular level. More recently, the application of gene therapy for the treatment of human diseases, either inherited (e.g., ADA deficiency) or acquired (e.g., cancer or infectious disease), has received considerable attention. With the advent of improved gene transfer techniques and the identification of an ever expanding library of "defective gene"-related diseases, gene therapy has rapidly evolved from a treatment theory to a practical reality.

Traditionally, gene therapy has been defined as a procedure in which an exogenous gene is introduced into the cells of a patient in order to correct an inborn genetic error. Although more than 4500 human diseases are currently classified as genetic, specific mutations in the human genome have been identified for relatively few of these diseases. Until recently, these rare genetic diseases represented the exclusive targets of gene therapy efforts. Accordingly, most of the NIH approved gene therapy protocols to date have been directed toward the introduction of a functional copy of a defective gene into the somatic cells of an individual having a known inborn genetic error. Only recently, have researchers and clinicians begun to appreciate that most human cancers, certain forms of cardiovascular disease, and many degenerative diseases also have important genetic components, and for the purposes of designing novel gene therapies, should be considered "genetic disorders." Therefore, gene therapy has more recently been broadly defined as the correction of a disease phenotype through the introduction of new genetic information into the affected organism.

Two basic approaches to gene therapy have evolved: (1) ex vivo gene therapy and (2) in vivo gene therapy. In ex vivo gene therapy, cells are removed from a subject and cultured in vitro. A functional replacement gene is introduced into the cells (transfection) in vitro, the modified cells are expanded  
5 in culture, and then reimplanted in the subject. These genetically modified, reimplanted cells are reported to secrete detectable levels of the transfected gene product in situ. The development of improved retroviral gene transfer methods (transduction) has greatly facilitated the transfer into and subsequent expression of genetic material by somatic cells. Accordingly, retrovirus-mediated gene  
10 transfer has been used in clinical trials to mark autologous cells and as a way of treating genetic disease.

In in vivo gene therapy, target cells are not removed from the subject. Rather, the transferred gene is introduced into cells of the recipient organism in situ that is, within the recipient. In vivo gene therapy has been examined in  
15 several animal models. Several recent publications have reported the feasibility of direct gene transfer in situ into organs and tissues such as muscle, hematopoietic stem cells, the arterial wall, the nervous system, and lung. Direct injection of DNA into skeletal muscle, heart muscle and injection of DNA-lipid complexes into the vasculature also has been reported to yield a detectable  
20 expression level of the inserted gene product(s) in vivo.

Treatment of inherited genetic diseases of the brain remains an intractable problem. An example of such are the lysosomal storage diseases. Collectively, the incidence of lysosomal storage diseases (LSD) is 1 in 12,000 births world wide, and in 58% of cases, there is significant central nervous  
25 system (CNS) involvement (Meikle et al., JAMA 281:249-254, 1999). Proteins deficient in these disorders, when delivered intravenously, do not cross the blood-brain barrier, or, when delivered directly to the brain, are not widely distributed. Injection of viral vectors expressing recombinant lysosomal proteins, a proportion of which is secreted, can result in significant spread of  
30 enzyme in murine cerebrum. However, methods to improve the distribution of enzyme following intraventricular injection of recombinant protein, or from transduced cells, are required for approaching therapies in the significantly larger brains of humans. Similar to lysosomal storage diseases, approaching global therapy for degenerative diseases due to polyglutamine repeat expansion or



transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase.

5 However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Additionally, multiple copies of the nucleic acid encoding enzymes may be linked together in the expression vector. Such multiple nucleic acids  
10 may be separated by linkers. The vector may be an adenoviral vector, an adeno-associated virus (AAV) vector, a retrovirus, or a lentivirus vector based on human immunodeficiency virus or feline immunodeficiency virus. Examples of such AAVs are found in Davidson et al., PNAS (2000) 97:3428-3432. The AAV and lentiviruses could confer lasting expression while the adenovirus  
15 would provide transient expression.

The present invention also provides a mammalian cell containing the expression vector described above. The cell may be human, and may be from spleen, kidney, lung, heart, liver or brain. The cell type may be a stem or progenitor cell population.

20 The present invention provides a method of treating a genetic disease or cancer in a mammal by administering a polynucleotide, polypeptide, expression vector, or cell described above. The genetic disease or cancer may be a lysosomal storage disease (LSD) such as infantile or late infantile ceroid lipofuscinoses, Gaucher, Juvenile Batten, Fabry, MLD, Sanfilippo A, Late  
25 Infantile Batten, Hunter, Krabbe, Morquio, Pompe, Niemann-Pick C, Tay-Sachs, Hurler (MPS-I H), Sanfilippo B, Maroteaux-Lamy, Niemann-Pick A, Cystinosis, Hurler-Scheie (MPS-I H/S), Sly Syndrome (MPS VII), Scheie (MPS-I S), Infantile Batten, GM1 Gangliosidosis, Mucopolipidosis type II/III, or Sandhoff disease. Alternatively, the genetic disease may be a neurodegenerative  
30 disease, such as Huntington's disease, ALS, hereditary spastic hemiplegia, primary lateral sclerosis, spinal muscular atrophy, Kennedy's disease, Alzheimer's disease, a polyglutamine repeat disease, or focal exposure such as Parkinson's disease.

In general, the invention relates to polynucleotides, polypeptides, vectors, and genetically engineered cells (modified *ex vivo* or *in vivo*), and the use of them. In particular, the invention relates to a method for gene or protein therapy that is capable of both localized and systemic delivery of a therapeutically effective dose of the therapeutic agent.

According to one aspect of the invention, a cell expression system for expressing a therapeutic agent in a mammalian recipient is provided. The expression system (also referred to herein as a "genetically modified cell") comprises a cell and an expression vector for expressing the therapeutic agent.

Expression vectors of the instant invention include, but are not limited to, viruses, plasmids, and other vehicles for delivering heterologous genetic material to cells. Accordingly, the term "expression vector" as used herein refers to a vehicle for delivering heterologous genetic material to a cell. In particular, the expression vector is a recombinant adenoviral, adeno-associated virus, or lentivirus or retrovirus vector.

The expression vector further includes a promoter for controlling transcription of the heterologous gene. The promoter may be an inducible promoter (described below). The expression system is suitable for administration to the mammalian recipient. The expression system may comprises a plurality of non-immortalized genetically modified cells, each cell containing at least one recombinant gene encoding at least one therapeutic agent.

The cell expression system can be formed *ex vivo* or *in vivo*. To form the expression system *ex vivo*, one or more isolated cells are transduced with a virus or transfected with a nucleic acid or plasmid *in vitro*. The transduced or transfected cells are thereafter expanded in culture and thereafter administered to the mammalian recipient for delivery of the therapeutic agent *in situ*. The genetically modified cell may be an autologous cell, i.e., the cell is isolated from the mammalian recipient. The genetically modified cell(s) are administered to the recipient by, for example, implanting the cell(s) or a graft (or capsule) including a plurality of the cells into a cell-compatible site of the recipient.

According to yet another aspect of the invention, a method for treating a mammalian recipient *in vivo* is provided. The method includes introducing an expression vector for expressing a heterologous gene product into a cell of the patient *in situ*. To form the expression system *in vivo*, an expression vector for

expressing the therapeutic agent is introduced in vivo into target location of the mammalian recipient by, for example, intraperitoneal injection or injection directly into the brain.

According to yet another aspect of the invention, a method for treating a mammalian recipient in vivo is provided. The method includes introducing the recombinant PTD-fusion protein into the tissues of the patient in vivo. The therapeutic agent is introduced in vivo into target location of the mammalian recipient by, for example, a pump to provide continuous delivery into brain ventricles.

The expression vector for expressing the heterologous gene may include an inducible promoter for controlling transcription of the heterologous gene product. Accordingly, delivery of the therapeutic agent in situ is controlled by exposing the cell in situ to conditions, which induce transcription of the heterologous gene.

The mammalian recipient may have a condition that is amenable to gene replacement therapy. As used herein, "gene replacement therapy" refers to administration to the recipient of exogenous genetic material encoding a therapeutic agent and subsequent expression of the administered genetic material in situ. Thus, the phrase "condition amenable to gene replacement therapy" embraces conditions such as genetic diseases (i.e., a disease condition that is attributable to one or more gene defects), acquired pathologies (i.e., a pathological condition which is not attributable to an inborn defect), cancers and prophylactic processes (i.e., prevention of a disease or of an undesired medical condition). Accordingly, as used herein, the term "therapeutic agent" refers to any agent or material, which has a beneficial effect on the mammalian recipient. Thus, "therapeutic agent" embraces both therapeutic and prophylactic molecules having nucleic acid or protein components.

According to one embodiment, the mammalian recipient has a genetic disease and the exogenous genetic material comprises a heterologous gene encoding a therapeutic agent for treating the disease. In yet another embodiment, the mammalian recipient has an acquired pathology and the exogenous genetic material comprises a heterologous gene encoding a therapeutic agent for treating the pathology. According to another embodiment, the patient has a cancer and the exogenous genetic material comprises a

heterologous gene encoding an anti-neoplastic agent. In yet another embodiment the patient has an undesired medical condition and the exogenous genetic material comprises a heterologous gene encoding a therapeutic agent for treating the condition.

5           According to yet another embodiment, a pharmaceutical composition is disclosed. The pharmaceutical composition comprises a plurality of the above-described genetically modified cells or polypeptides and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for treating a condition amenable to gene replacement therapy and the exogenous genetic  
10   material comprises a heterologous gene encoding a therapeutic agent for treating the condition. The pharmaceutical composition may contain an amount of genetically modified cells or polypeptides sufficient to deliver a therapeutically effective dose of the therapeutic agent to the patient. Exemplary conditions amenable to gene replacement therapy are described below.

15           According to another aspect of the invention, a method for forming the above-described pharmaceutical composition is provided. The method includes introducing an expression vector for expressing a heterologous gene product into a cell to form a genetically modified cell and placing the genetically modified cell in a pharmaceutically acceptable carrier.

20           According to still another aspect of the invention, a cell graft is disclosed. The graft comprises a plurality of genetically modified cells attached to a support, which is suitable for implantation into the mammalian recipient. The support may be formed of a natural or synthetic material.

          According to still another aspect of the invention, an encapsulated cell  
25   expression system is disclosed. The encapsulated expression system comprises a plurality of genetically modified cells contained within a capsule, which is suitable for implantation into the mammalian recipient. The capsule may be formed of a natural or synthetic material. The capsule containing the plurality of genetically modified cells may be implanted in the peritoneal cavity, the brain or  
30   ventricles in the brain, or into the specific disease site.

          According to still another aspect of the invention, a protein delivery method is disclosed. The protein is purified from genetically modified cells and then placed into the mammalian recipient. The purified protein is placed into the brain, into the peritoneum, or into the specific disease site.



These and other aspects of the invention as well as various advantages and utilities will be more apparent with reference to the detailed description of the invention and to the accompanying Figures.

As used herein, the term “lysosomal enzyme,” a “secreted protein,” a  
5 “nuclear protein,” a “cytoplasmic protein,” or a “Tat protein transduction domain” include variants or biologically active or inactive fragments of these polypeptides. A “variant” of one of the polypeptides is a polypeptide that is not completely identical to a native protein. Such variant protein can be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or  
10 more amino acid. The amino acid sequence of the protein is modified, for example by substitution, to create a polypeptide having substantially the same or improved qualities as compared to the native polypeptide. The substitution may be a conserved substitution. A “conserved substitution” is a substitution of an amino acid with another amino acid having a similar side chain. A conserved  
15 substitution would be a substitution with an amino acid that makes the smallest change possible in the charge of the amino acid or size of the side chain of the amino acid (alternatively, in the size, charge or kind of chemical group within the side chain) such that the overall peptide retains its spacial conformation but has altered biological activity. For example, common conserved changes might  
20 be Asp to Glu, Asn or Gln; His to Lys, Arg or Phe; Asn to Gln, Asp or Glu and Ser to Cys, Thr or Gly. Alanine is commonly used to substitute for other amino acids. The 20 essential amino acids can be grouped as follows: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine having nonpolar side chains; glycine, serine, threonine, cystine, tyrosine, asparagine and  
25 glutamine having uncharged polar side chains; aspartate and glutamate having acidic side chains; and lysine, arginine, and histidine having basic side chains. Stryer, L. *Biochemistry* (2d edition) W. H. Freeman and Co. San Francisco (1981), p. 14-15; Lehninger, A. *Biochemistry* (2d ed., 1975), p. 73-75.

The amino acid changes are achieved by changing the codons of the  
30 corresponding nucleic acid sequence. It is known that such polypeptides can be obtained based on substituting certain amino acids for other amino acids in the polypeptide structure in order to modify or improve biological activity. For example, through substitution of alternative amino acids, small conformational changes may be conferred upon a polypeptide which result in increased.

Alternatively, amino acid substitutions in certain polypeptides may be used to provide residues, which may then be linked to other molecules to provide peptide-molecule conjugates which, retain sufficient properties of the starting polypeptide to be useful for other purposes.

5           One can use the hydropathic index of amino acids in conferring interactive biological function on a polypeptide, wherein it is found that certain amino acids may be substituted for other amino acids having similar hydropathic indices and still retain a similar biological activity. Alternatively, substitution of like amino acids may be made on the basis of hydrophilicity, particularly where  
10 the biological function desired in the polypeptide to be generated is intended for use in immunological embodiments. The greatest local average hydrophilicity of a "protein", as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity. U.S. Patent 4,554,101. Accordingly, it is noted that substitutions can be made based on the hydrophilicity assigned to each  
15 amino acid.

In using either the hydrophilicity index or hydropathic index, which assigns values to each amino acid, it is preferred to conduct substitutions of amino acids where these values are  $\pm 2$ , with  $\pm 1$  being particularly preferred, and those with in  $\pm 0.5$  being the most preferred substitutions.

20           The variant protein has at least 50%, at least about 80%, or even at least about 90% but less than 100%, contiguous amino acid sequence homology or identity to the amino acid sequence of a corresponding native protein.

The amino acid sequence of the variant polypeptide corresponds essentially to the native polypeptide's amino acid sequence. As used herein  
25 "correspond essentially to" refers to a polypeptide sequence that will elicit a biological response substantially the same as the response generated by the native protein. Such a response may be at least 60% of the level generated by the native protein, and may even be at least 80% of the level generated by native protein.

30           A variant of the invention may include amino acid residues not present in the corresponding native protein or deletions relative to the corresponding native protein. A variant may also be a truncated "fragment" as compared to the corresponding native protein, *i.e.*, only a portion of a full-length protein. Protein variants also include peptides having at least one D-amino acid.

The variant protein of the present invention may be expressed from an isolated DNA sequence encoding the variant protein. "Recombinant" is defined as a peptide or nucleic acid produced by the processes of genetic engineering. It should be noted that it is well-known in the art that, due to the redundancy in the genetic code, individual nucleotides can be readily exchanged in a codon, and still result in an identical amino acid sequence. The terms "protein," "peptide" and "polypeptide" are used interchangeably herein.

### **Brief Description of the Drawings**

**Figure 1.**  $\beta$ -glucuronidase-Tat expression vectors. **(a)** Cartoon depicting the orientation of the Tat motifs at the carboxy termini of  $\beta$ -glucuronidase. The  $\beta$ -glucuronidase sequences were cloned into the E1 region of Ad shuttle plasmids, and the shuttles recombined with Ad backbones expressing GFP in the E3 region. The resultant viruses expressed  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> in E1 and GFP in E3. Both transgenes are driven off the RSV promoter. **(b-d)**,  $\beta$ -glucuronidase activity after incubation of A549 cells with the recombinant proteins  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub>, respectively. Using the assay conditions described in the Examples below the background levels of  $\beta$ -glucuronidase staining is very low (inset, panel b). The uptake of both native and tat-modified  $\beta$ -glucuronidase (inset, panel d) was notably punctate. **(e-g)**,  $\beta$ -glucuronidase activity after incubation of A549 cells with the recombinant proteins  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> in the presence of D-mannose-6-phosphate. Bars = 50  $\mu$ m. **(h)**, Table indicating  $\beta$ -glucuronidase activity.

**Figure 2.** eGFP and  $\beta$ -glucuronidase activity in sections of murine liver after i.v. injection of vectors expressing native or Tat-modified  $\beta$ -glucuronidase. **(a-c)**, photomicrographs showing representative levels of GFP expression in murine liver following injection of Ad $\beta$ gluc, Ad $\beta$ glucTat<sub>47-57</sub> or Ad $\beta$ glucTat<sub>57-47</sub>, respectively. **(d-f)**, sections from mice transduced with Ad $\beta$ gluc, Ad $\beta$ glucTat<sub>47-57</sub> or Ad $\beta$ glucTat<sub>57-47</sub>, respectively, stained *in situ* for  $\beta$ -glucuronidase activity. Bar = 200  $\mu$ m.

**Figure 3.**  $\beta$ -glucuronidase activity in non-hepatic tissues after i.v. injection of mice with vectors expressing native or Tat-modified  $\beta$ -



inhibition of cognitive decline required that treatment be initiated in the neonatal period systemically prior to blood-brain barrier (BBB) closure (O'Connor, *et al.*, (1998) *J.Clin.Invest.* **101**:1394-1400), or directly to brain (Frisella, *et al.*, (2001) *Mol.Ther.* (In Press)).

5           Recent work showed that the 11 amino acid motif from HIV Tat known as the protein transduction domain (PTD) improved the biodistribution of recombinant reporter proteins following systemic delivery (Fawell, *et al.*, (1994). *Proc.Natl.Acad.Sci.U.S.A.* **91**:664-668), (Schwarze, *et al.*, (1999) *Science* **285**:1569-1572). When partially denatured, the protein was capable of crossing  
10 the blood brain barrier of adult mice (Schwarze, *et al.*, (1999) *Science* **285**:1569-1572). These findings suggest that gene therapy with vectors engineered to express Tat-modified recombinant lysosomal proteins from systemic sources *in vivo* could be used to improve their biodistribution.

To test this, fusion proteins of human  $\beta$ -glucuronidase and the 11 amino  
15 acid PTD from HIV Tat were engineered in recombinant adenovirus expression vectors (**Fig. 1a**). As peptides representative of the PTDs from *Drosophila* antennapedia can translocate across cell membranes in either orientation (Derossi, *et al.*, (1996) *J.Biol.Chem.* **271**(30):18188-18193) fusion proteins with the HIV Tat peptide in the 47-57 and 57-47 orientation were generated. We first  
20 examined the properties of the modified  $\beta$ -glucuronidase for mannose-6 phosphate (M6P) dependent and independent entry into cells. HeLa cells were infected with 20 infectious units (i.u.)/cell of recombinant vectors expressing unmodified  $\beta$ -glucuronidase (Ad $\beta$ gluc),  $\beta$ -glucuronidase-Tat<sub>47-57</sub> (Ad $\beta$ gluc-Tat<sub>47-57</sub>) or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> (Ad $\beta$ gluc-Tat<sub>57-47</sub>). Three days later, supernatants  
25 were collected and  $\beta$ -glucuronidase activity quantified. The Tat modification to the COOH-terminus did not inhibit enzyme activity. Equivalent units of  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> were added to the media of A549 cells in the presence or absence of M6P (**Fig. 1b-g**). While all recombinant proteins entered cells readily (**Fig. 1b-d**), M6P dramatically  
30 inhibited the uptake of native  $\beta$ -glucuronidase (**Fig. 1e**) relative to  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> (**Fig. 1f,g**) as assayed by an *in situ* activity stain (Ghodsi, *et al.*, (1998) *Hum.Gene Ther.* **9**:2331-2340). Quantitation of enzyme activity showed that M6P inhibited 100% of uptake of native  $\beta$ -glucuronidase.  $\beta$ -Glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub>,

were inhibited by 24 and 51%, respectively (**Fig. 1h**). Thus  $\beta$ -glucuronidase modified at the COOH terminus with the PTD of Tat allowed for both M6P dependent and independent entry. Similar results were found when the wild type and Tat-modified  $\beta$ -glucuronidase-containing supernatants were added to  
5 cultures of NIH 3T3 cells with or without M6P.

Earlier studies showed that uptake of Tat-modified proteins occurred by adsorptive endocytosis in cell lines and primary cell cultures (Fawell, *et al.*, (1994) *Proc.Natl.Acad.Sci.U.S.A.* **91**:664-668), (Mann, *et al.*, (1991) *EMBO J.* **10**(7):1733-1739). Mann and Frankel also showed that entry of [<sup>125</sup>I] Tat was  
10 temperature dependent (Mann, *et al.*, (1991) *EMBO J.* **10**(7):1733-1739). This is distinct from peptides representative of the PTD from antenopodia, which enters cells readily at 4 and 37 °C (Derossi, *et al.*, (1996) *J.Biol.Chem.* **271**(30):18188-18193). Equivalent units of  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> were added to cells and uptake at 4 and 37 °C measured  
15 and compared. In all cases, enzyme uptake at 4 °C was dramatically inhibited compared to that occurring at 37 °C. These data, and the observation that histochemical staining for enzyme activity at time points early after enzyme addition was punctate (Fig 1d, inset), suggests that Tat-modified  $\beta$ -glucuronidase, like native  $\beta$ -glucuronidase, enters cells in part through endocytic  
20 mechanisms.

We next investigated Ad $\beta$ gluc, Ad $\beta$ gluc-Tat<sub>47-57</sub> and Ad $\beta$ gluc-Tat<sub>57-47</sub> *in vivo*. Viruses were injected into mice tail veins, which results in transduction of hepatocytes (Stein, *et al.*, (1999) *J.Virol.* **73**(4):3424-3429). The vectors used in this study also expressed GFP in the E3 region to permit detection of infected  
25 cells (GFP positive) relative to  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> activity. Sections of liver analyzed 10 days after i.v. vector injection show roughly equivalent levels of GFP expression for all viruses (**Fig. 2a-c**), but varied distribution of  $\beta$ -glucuronidase activity (**Fig. 2d-f**).  $\beta$ -Glucuronidase-Tat<sub>47-57</sub> and  $\beta$ -glucuronidase-Tat<sub>57-47</sub> activity were detected  
30 throughout the parenchyma of the liver as evidenced by *in situ* enzyme activity assay (**Fig. 2e,f**). In contrast, transduction with Ad $\beta$ gluc resulted in focal staining (**Fig. 2d**).

Similar to native  $\beta$ -glucuronidase (Stein, *et al.*, (1999) *J.Virol.* **73**(4):3424-3429), we also noted spread of  $\beta$ -glucuronidase-Tat<sub>47-57</sub> and  $\beta$ -

glucuronidase-Tat<sub>57-47</sub> to other tissues (**Fig. 3**). In some instances the penetration of the enzyme within specific organs or tissues was remarkably distinct from native  $\beta$ -glucuronidase. For example, in the spleen (**Fig. 3a,b**), extensive  $\beta$ -glucuronidase activity was found in the marginal zone and to a limited extent in the red pulp after transduction with Adgluc. However,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> fully penetrated the red pulp (**Fig. 3b**).  $\beta$ -glucuronidase-Tat<sub>57-47</sub> was comparable. Interestingly,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> distribution was similar to sections from mice receiving i.p. injections of partially denatured, purified *E. coli*  $\beta$ -galactosidase-Tat fusion proteins (Schwarze, *et al.*, (1999) *Science* 285:1569-1572).

We also noted increased levels of enzyme in kidney (**Fig. 3c,d**), lung (**Fig. 3e,f**) heart (**Fig. 3g,h**), and skeletal muscle for  $\beta$ -glucuronidase-Tat<sub>47-57</sub> and  $\beta$ -glucuronidase-Tat<sub>57-47</sub>. Although the distribution of  $\beta$ -glucuronidase activity was widespread in kidney and lung in Ad $\beta$ glucTat<sub>47-57</sub> vs. Ad $\beta$ gluc treated mice,  $\beta$ -glucuronidase activity remained undetectable in both lung lavage fluid and urine.

In contrast to earlier studies with recombinant protein (Schwarze, *et al.*, (1999) *Science* 285:1569-1572), we noted only a modest increase in enzyme staining in brain, all limited to the choroid plexus (**Fig. 3i,j**). Quantitative enzyme assay of brain lysates indicated that there were no significant differences between the treatment groups (**Fig. 3k**). Together the data suggest that the 11 amino acid PTD from Tat may alter the biodistribution of native proteins expressed and secreted *in vivo* from transduced cells. However the addition of the Tat motif to  $\beta$ -glucuronidase, expressed from systemically transduced tissues of adult mice, does not significantly improve enzyme levels within brain. Possibilities for the discrepancies include differences in the type of protein delivered. Dowdy and colleagues achieved penetration of the blood brain barrier with denatured/partially renatured  $\beta$ -galactosidase. Fawell and colleagues used native  $\beta$ -galactosidase-Tat conjugates in their studies, and did not see penetration of the brain. Both studies delivered approximately  $4 \times 10^{-9}$  mole of  $\beta$ -galactosidase by intraperitoneal injection, for an estimated serum concentration of 1  $\mu$ M. In our studies, the Tat-modified  $\beta$ -glucuronidase reached an approximate serum concentration of 16 nM, and likely remained in native conformation.

It is not known if the partially-denatured, Tat-modified reporters described by Dowdy and colleagues can pass an intact blood brain barrier in larger animal models. It would also be important to know if the Tat-motifs could impart improved distribution of proteins when administered directly to, or  
5 expressed from, cells within the brain. To determine this, vectors expressing  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> ( $2 \times 10^7$  i.u.) were injected into the right hemisphere, and animals sacrificed 10 days later. All vectors yielded nearly equivalent levels of GFP expression (**Fig. 4a,b**). However, the addition of the Tat motif to  $\beta$ -glucuronidase resulted in  
10 significantly greater distribution of enzyme compared to the non-modified protein (**Fig. 4. c vs. d**). As a consequence, there was a 1.5 - fold increase in the volume of brain positive for  $\beta$ -glucuronidase activity (**Fig. 4e**), and a notable increase in the levels of  $\beta$ -glucuronidase activity in the contralateral hemisphere (**Fig. 4f**).

15 Ventricular administration of secreted proteins for the MPS or other lysosomal storage diseases would be preferred over multiple parenchymal injections if adequate spread of enzyme into the parenchyma can occur. Injection of the recombinant vectors into the lateral ventricles of mice led to significant transduction of ependyma as evidenced by GFP fluorescence (**Fig. 5a,c**) (Ghodsi, *et al.*, (1999) *Exp.Neurol.* **160**:109-116). As shown previously,  $\beta$ -  
20 glucuronidase expression from Ad $\beta$ gluc was obvious in areas immediately adjacent to the ependyma (**Fig. 5d**). However, the penetration of  $\beta$ -glucuronidase-Tat was remarkably enhanced, resulting in significant increases in the volume of brain positive for active enzyme (**Fig. 5g**). In animals receiving  
25 intraventricular injection of Ad $\beta$ gluc, 5% of the brain was  $\beta$ -glucuronidase positive. In contrast, expression of  $\beta$ -glucuronidase-Tat<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat<sub>57-47</sub> was distributed in 22 and 30% of the brain, respectively. Increased distribution of expressed enzyme after intraventricular injection has important implications for enzyme-based therapy or for gene therapy using vectors with  
30 high affinity to the ependymal lining, such as recombinant adenoviruses (Ghodsi, *et al.*, (1999) *Exp.Neurol.* **160**:109-116) and adeno-associated virus type 4 (Davidson, *et al.*, (2000) *Proc.Natl.Acad.Sci.U.S.A.* **97**(7):3428-3432).

Prior to this work, PTDs had been applied as synthetic peptides or used to improve transfer of nuclear and cytoplasmic proteins. We show that the PTD



from HIV Tat allowed for significant improvements in the distribution of a lysosomal protein expressed and secreted from cells after viral-mediated gene transfer to liver and brain. When ependyma lining the ventricles were transduced, there was a 5 to 7 fold increase in the volume of brain positive for  $\beta$ -glucuronidase activity. Thus PTDs could also dramatically improve the biodistribution of recombinant enzyme following intraventricular injection. Together, our data represent a significant improvement in the development of gene and protein therapies for inherited genetic diseases affecting the brain.

The present invention provides methods of treating a genetic disease or cancer in a mammal by administering a polynucleotide, polypeptide, expression vector, or cell. For the gene therapy methods, a person having ordinary skill in the art of molecular biology and gene therapy would be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the polynucleotide, polypeptide, or expression vector used in the novel methods of the present invention.

The instant invention provides a cell expression system for expressing exogenous genetic material in a mammalian recipient. The expression system, also referred to as a "genetically modified cell", comprises a cell and an expression vector for expressing the exogenous genetic material. The genetically modified cells are suitable for administration to a mammalian recipient, where they replace the endogenous cells of the recipient. Thus, the genetically modified cells may be non-immortalized and are non-tumorigenic.

According to one embodiment, the cells are transformed or otherwise genetically modified ex vivo. The cells are isolated from a mammal (for example, a human), transformed (i.e., transduced or transfected in vitro) with a vector for expressing a heterologous (e.g., recombinant) gene encoding the therapeutic agent, and then administered to a mammalian recipient for delivery of the therapeutic agent in situ. The mammalian recipient may be a human and the cells to be modified are autologous cells, i.e., the cells are isolated from the mammalian recipient.

According to another embodiment, the cells are transformed or otherwise genetically modified in vivo. The cells from the mammalian recipient are transformed (i.e., transduced or transfected) in vivo with a vector containing

exogenous genetic material for expressing a heterologous (e.g., recombinant) gene encoding a therapeutic agent and the therapeutic agent is delivered in situ.

As used herein, "exogenous genetic material" refers to a nucleic acid or an oligonucleotide, either natural or synthetic, that is not naturally found in the cells; or if it is naturally found in the cells, it is not transcribed or expressed at biologically significant levels by the cells. Thus, "exogenous genetic material" includes, for example, a non-naturally occurring nucleic acid that can be transcribed into anti-sense RNA, as well as a "heterologous gene" (i.e., a gene encoding a protein which is not expressed or is expressed at biologically insignificant levels in a naturally-occurring cell of the same type).

In the certain embodiments, the mammalian recipient has a condition that is amenable to gene replacement therapy. As used herein, "gene replacement therapy" refers to administration to the recipient of exogenous genetic material encoding a therapeutic agent and subsequent expression of the administered genetic material in situ. Thus, the phrase "condition amenable to gene replacement therapy" embraces conditions such as genetic diseases (i.e., a disease condition that is attributable to one or more gene defects), acquired pathologies (i.e., a pathological condition which is not attributable to an inborn defect), cancers and prophylactic processes (i.e., prevention of a disease or of an undesired medical condition). Accordingly, as used herein, the term "therapeutic agent" refers to any agent or material, which has a beneficial effect on the mammalian recipient. Thus, "therapeutic agent" embraces both therapeutic and prophylactic molecules having nucleic acid (e.g., antisense RNA) and/or protein components.

A number of lysosomal storage diseases are known (for example Neimann-Pick disease, Sly syndrome, Gaucher Disease). Other examples of lysosomal storage diseases are provided in Table 1. Therapeutic agents effective against these diseases are also known, since it is the protein/enzyme known to be deficient in these disorders.

Table 1. List of putative target diseases for PTD-based therapies.

<b>Disease<sup>a</sup></b>	<b>Post-natal<sup>b</sup></b>	<b>%</b>	
Gaucher	71	13.0	
Juvenile Batten	39	7.2	
Fabry	36	6.6	% LSDs with CNS involvement
MLD	35	6.4	58.317757
Sanfilippo A	33	6.1	
Late Infantile Batten	27	5.0	
Hunter	26	4.8	
Krabbe	21	3.9	
Morquio	21	3.9	
Pompe	21	3.9	
Niemann-Pick C	20	3.7	
Tay-Sachs	19	3.5	
Hurler (MPS-I H)	18	3.3	
Sanfilippo B	18	3.3	
Maroteaux-Lamy	17	3.1	
Niemann-Pick A	16	2.9	
Cystinosis	15	2.8	
Hurler-Scheie (MPS-I H/S)	10	1.8	
Sly Syndrome (MPS VII)	0	0	
Scheie (MPS-I S)	10	1.8	
Infantile Batten	10	1.8	
GM1 Gangliosidosis	10	1.8	
Mucopolidosis type II/III	10	1.8	
Sandhoff	10	1.8	
other	32	5.9	

<sup>a</sup>Diseases tested in a 16 year retrospective study in Australia (Menke et al, JAMA).

<sup>b</sup>prevalence from post-natal diagnoses only

5

As used herein, "acquired pathology" refers to a disease or syndrome manifested by an abnormal physiological, biochemical, cellular, structural, or molecular biological state. Exemplary acquired pathologies, are provided in Table 2. Therapeutic agents effective against these diseases are also given.

10

Table II. Potential Gene Therapies for Motor Neuron Diseases and other neurodegenerative diseases.

<b>Disease</b>	<b>Candidates for Gene Replacement<sup>2</sup></b>	<b>Candidates for Downstream Effectors<sup>3</sup></b>	<b>Neuronal or Progenitor Cell Replacement<sup>4</sup></b>
ALS	No	Yes	Yes
Hereditary spastic hemiplegia	Spastin, paraplegin	Yes	Yes
Primary lateral sclerosis <sup>5</sup>	No	Yes	Yes
Spinal muscular atrophy	Survival motor neuron gene, neuronal apoptosis inhibiting factor	Yes	Yes
Kennedy's disease	Androgen –receptor element	Yes	Yes
Alzheimer's disease		Yes	Yes
Polyglutamine Repeat Diseases		Yes	Yes

<sup>2</sup>Based on current literature.

5           <sup>3</sup>Based on current literature, includes calbindin, trophic factors, bcl-2, neurofilaments, and pharmacologic agents.

<sup>4</sup>May include cell- or cell- and gene-based therapies.

<sup>5</sup>A sporadic degeneration of corticospinal neurons, 1/100<sup>th</sup> as common as ALS, with no known genetic links.

10

Delivery of a therapeutic agent by a genetically modified cell is not limited to delivery to a particular location in the body in which the genetically modified cells would normally reside. Accordingly, the genetically modified cells of the invention are useful for delivering a therapeutic agent, such as a replacement protein, an anti-neoplastic agent, or a neuroprotective agent, to various parts or the appropriate part of the body.

15

Alternatively, the condition amenable to gene replacement therapy is a prophylactic process, i.e., a process for preventing disease or an undesired medical condition. Thus, the instant invention embraces a cell expression system for delivering a therapeutic agent that has a prophylactic function (i.e., a prophylactic agent) to the mammalian recipient.

In summary, the term "therapeutic agent" includes, but is not limited to, the agents listed in the Tables above, as well as their functional equivalents. As used herein, the term "functional equivalent" refers to a molecule (e.g., a peptide or protein) that has the same or an improved beneficial effect on the mammalian recipient as the therapeutic agent of which is it deemed a functional equivalent. As will be appreciated by one of ordinary skill in the art, a functionally equivalent proteins can be produced by recombinant techniques, e.g., by expressing a "functionally equivalent DNA". As used herein, the term "functionally equivalent DNA" refers to a non-naturally occurring DNA, which encodes a therapeutic agent. For example, many, if not all, of the agents disclosed in Tables 1-3 have known amino acid sequences, which are encoded by naturally occurring nucleic acids. However, due to the degeneracy of the genetic code, more than one nucleic acid can encode the same therapeutic agent. Accordingly, the instant invention embraces therapeutic agents encoded by naturally-occurring DNAs, as well as by non-naturally-occurring DNAs, which encode the same protein as, encoded by the naturally-occurring DNA.

The above-disclosed therapeutic agents and conditions amenable to gene replacement therapy are merely illustrative and are not intended to limit the scope of the instant invention. The selection of a suitable therapeutic agent for treating a known condition is deemed to be within the scope of one of ordinary skill of the art without undue experimentation.

#### Methods for Introducing Genetic Material into Cells

The exogenous genetic material (e.g., a cDNA encoding one or more therapeutic proteins) is introduced into the cell ex vivo or in vivo by genetic transfer methods, such as transfection or transduction, to provide a genetically modified cell. Various expression vectors (i.e., vehicles for facilitating delivery of exogenous genetic material into a target cell) are known to one of ordinary skill in the art.

As used herein, "transfection of cells" refers to the acquisition by a cell of new genetic material by incorporation of added DNA. Thus, transfection refers to the insertion of nucleic acid into a cell using physical or chemical methods. Several transfection techniques are known to those of ordinary skill in the art including: calcium phosphate DNA co-precipitation (Methods in  
5 Molecular Biology, Vol. 7, Gene Transfer and Expression Protocols, Ed. E. J. Murray, Humana Press (1991)); DEAE-dextran (supra); electroporation (supra); cationic liposome-mediated transfection (supra); and tungsten particle-facilitated microparticle bombardment (Johnston, S. A., Nature 346:776-777 (1990)).  
10 Strontium phosphate DNA co-precipitation (Brash D. E. et al. Molec. Cell. Biol. 7:2031-2034 (1987) is another possible transfection method.

In contrast, "transduction of cells" refers to the process of transferring nucleic acid into a cell using a DNA or RNA virus. A RNA virus (i.e., a retrovirus) for transferring a nucleic acid into a cell is referred to herein as a  
15 transducing chimeric retrovirus. Exogenous genetic material contained within the retrovirus is incorporated into the genome of the transduced cell. A cell that has been transduced with a chimeric DNA virus (e.g., an adenovirus carrying a cDNA encoding a therapeutic agent), will not have the exogenous genetic material incorporated into its genome but will be capable of expressing the  
20 exogenous genetic material that is retained extrachromosomally within the cell.

Typically, the exogenous genetic material includes the heterologous gene (usually in the form of a cDNA comprising the exons coding for the therapeutic protein) together with a promoter to control transcription of the new gene. The promoter characteristically has a specific nucleotide sequence necessary to  
25 initiate transcription. Optionally, the exogenous genetic material further includes additional sequences (i.e., enhancers) required to obtain the desired gene transcription activity. For the purpose of this discussion an "enhancer" is simply any non-translated DNA sequence which works contiguous with the coding sequence (in cis) to change the basal transcription level dictated by the  
30 promoter. The exogenous genetic material may introduced into the cell genome immediately downstream from the promoter so that the promoter and coding sequence are operatively linked so as to permit transcription of the coding sequence. A retroviral expression vector may include an exogenous promoter element to control transcription of the inserted exogenous gene. Such exogenous

promoters include both constitutive and inducible promoters.

Naturally-occurring constitutive promoters control the expression of essential cell functions. As a result, a gene under the control of a constitutive promoter is expressed under all conditions of cell growth. Exemplary  
5 constitutive promoters include the promoters for the following genes which encode certain constitutive or "housekeeping" functions: hypoxanthine phosphoribosyl transferase (HPRT), dihydrofolate reductase (DHFR) (Scharfmann et al., Proc. Natl. Acad. Sci. USA 88: 4626-4630 (1991)), adenosine deaminase, phosphoglycerol kinase (PGK), pyruvate kinase,  
10 phosphoglycerol mutase, the  $\alpha$ -actin promoter (Lai et al., Proc. Natl. Acad. Sci. USA 86: 10006-10010 (1989)), and other constitutive promoters known to those of skill in the art. In addition, many viral promoters function constitutively in eucaryotic cells. These include: the early and late promoters of SV40; the long terminal repeats (LTRs) of Moloney Leukemia Virus and other retroviruses; and  
15 the thymidine kinase promoter of Herpes Simplex Virus, among many others. Accordingly, any of the above-referenced constitutive promoters can be used to control transcription of a heterologous gene insert.

Genes that are under the control of inducible promoters are expressed only or to a greater degree, in the presence of an inducing agent, (e.g.,  
20 transcription under control of the metallothionein promoter is greatly increased in presence of certain metal ions). Inducible promoters include responsive elements (REs) which stimulate transcription when their inducing factors are bound. For example, there are REs for serum factors, steroid hormones, retinoic acid and cyclic AMP. Promoters containing a particular RE can be chosen in  
25 order to obtain an inducible response and in some cases, the RE itself may be attached to a different promoter, thereby conferring inducibility to the recombinant gene. Thus, by selecting the appropriate promoter (constitutive versus inducible; strong versus weak), it is possible to control both the existence and level of expression of a therapeutic agent in the genetically modified cell. If  
30 the gene encoding the therapeutic agent is under the control of an inducible promoter, delivery of the therapeutic agent in situ is triggered by exposing the genetically modified cell in situ to conditions for permitting transcription of the therapeutic agent, e.g., by intraperitoneal injection of specific inducers of the inducible promoters which control transcription of the agent. For example, in

situ expression by genetically modified cells of a therapeutic agent encoded by a gene under the control of the metallothionein promoter, is enhanced by contacting the genetically modified cells with a solution containing the appropriate (i.e., inducing) metal ions in situ.

5           Accordingly, the amount of therapeutic agent that is delivered in situ is regulated by controlling such factors as: (1) the nature of the promoter used to direct transcription of the inserted gene, (i.e., whether the promoter is constitutive or inducible, strong or weak); (2) the number of copies of the exogenous gene that are inserted into the cell; (3) the number of  
10   transduced/transfected cells that are administered (e.g., implanted) to the patient; (4) the size of the implant (e.g., graft or encapsulated expression system); (5) the number of implants; (6) the length of time the transduced/transfected cells or implants are left in place; and (7) the production rate of the therapeutic agent by the genetically modified cell. Selection and optimization of these factors for  
15   delivery of a therapeutically effective dose of a particular therapeutic agent is deemed to be within the scope of one of ordinary skill in the art without undue experimentation, taking into account the above-disclosed factors and the clinical profile of the patient.

          In addition to at least one promoter and at least one heterologous nucleic  
20   acid encoding the therapeutic agent, the expression vector may include a selection gene, for example, a neomycin resistance gene, for facilitating selection of cells that have been transfected or transduced with the expression vector. Alternatively, the cells are transfected with two or more expression vectors, at least one vector containing the gene(s) encoding the therapeutic agent(s), the  
25   other vector containing a selection gene. The selection of a suitable promoter, enhancer, selection gene and/or signal sequence (described below) is deemed to be within the scope of one of ordinary skill in the art without undue experimentation.

          The therapeutic agent can be targeted for delivery to an extracellular,  
30   intracellular or membrane location. If it is desirable for the gene product to be secreted from the cells, the expression vector is designed to include an appropriate secretion "signal" sequence for secreting the therapeutic gene product from the cell to the extracellular milieu. If it is desirable for the gene product to be retained within the cell, this secretion signal sequence is omitted.



In a similar manner, the expression vector can be constructed to include "retention" signal sequences for anchoring the therapeutic agent within the cell plasma membrane. For example, all membrane proteins have hydrophobic transmembrane regions, which stop translocation of the protein in the membrane and do not allow the protein to be secreted. The construction of an expression vector including signal sequences for targeting a gene product to a particular location is deemed to be within the scope of one of ordinary skill in the art without the need for undue experimentation.

The following discussion is directed to various utilities of the instant invention. For example, the instant invention has utility as an expression system suitable for detoxifying intra- and/or extracellular toxins in situ. By attaching or omitting the appropriate signal sequence to a gene encoding a therapeutic agent capable of detoxifying a toxin, the therapeutic agent can be targeted for delivery to the extracellular milieu, to the cell plasma membrane or to an intracellular location. In one embodiment, the exogenous genetic material containing a gene encoding an intracellular detoxifying therapeutic agent, further includes sequences encoding surface receptors for facilitating transport of extracellular toxins into the cell where they can be detoxified intracellularly by the therapeutic agent. Alternatively, the cells can be genetically modified to express the detoxifying therapeutic agent anchored within the cell plasma membrane such that the active portion extends into the extracellular milieu. The active portion of the membrane-bound therapeutic agent detoxifies toxins, which are present in the extracellular milieu.

In addition to the above-described therapeutic agents, some of which are targeted for intracellular retention, the instant invention also embraces agents intended for delivery to the extracellular milieu and/or agents intended to be anchored in the cell plasma membrane.

The selection and optimization of a particular expression vector for expressing a specific gene product in an isolated cell is accomplished by obtaining the gene, potentially with one or more appropriate control regions (e.g., promoter, insertion sequence); preparing a vector construct comprising the vector into which is inserted the gene; transfecting or transducing cultured cells in vitro with the vector construct; and determining whether the gene product is present in the cultured cells. In one embodiment, vectors for cell gene therapy

are viruses, such as replication-deficient viruses (described in detail below). Exemplary viral vectors are derived from: Harvey Sarcoma virus; ROUS Sarcoma virus, (MPSV); Moloney murine leukemia virus and DNA viruses (e.g., adenovirus) (Ternin, H., "Retrovirus vectors for gene transfer", in Gene Transfer, 5 Kucherlapati R, Ed., pp 149-187, Plenum, (1986)).

Replication-deficient retroviruses, including the recombinant lentivirus vectors, are neither capable of directing synthesis of virion proteins or making infectious particles. Accordingly, these genetically altered retroviral expression vectors have general utility for high-efficiency transduction of genes in cultured 10 cells, and specific utility for use in the method of the present invention. The lentiviruses, with their ability to transduce nondividing cells, have general utility for transduction of hepatocytes, cells in cerebrum, cerebellum and spinal cord, and also muscle and other slowly or non-dividing cells. Such retroviruses further have utility for the efficient transduction of genes into cells in vivo. 15 Retroviruses have been used extensively for transferring genetic material into cells. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles 20 from tissue culture media, and infection of the target cells with the viral particles) are provided in Kriegler, M. Gene Transfer and Expression, A Laboratory Manual, W.H. Freeman Co, New York, (1990) and Murray, E. J., ed. Methods in Molecular Biology, Vol. 7, Humana Press Inc., Clifton, N.J., (1991).

The major advantage of using retroviruses, including lentiviruses, for 25 gene therapy is that the viruses insert the gene encoding the therapeutic agent into the host cell genome, thereby permitting the exogenous genetic material to be passed on to the progeny of the cell when it divides. In addition, gene promoter sequences in the LTR region have been reported to enhance expression of an inserted coding sequence in a variety of cell types (see e.g., Hilberg et al., 30 Proc. Natl. Acad. Sci. USA 84:5232-5236 (1987); Holland et al., Proc. Natl. Acad. Sci. USA 84:8662-8666 (1987); Valerio et al., Gene 84:419-427 (1989). The major disadvantages of using a retrovirus expression vector are (1) insertional mutagenesis, i.e., the insertion of the therapeutic gene into an undesirable position in the target cell genome which, for example, leads to

unregulated cell growth and (2) the need for target cell proliferation in order for the therapeutic gene carried by the vector to be integrated into the target genome (Miller, D. G., et al., *Mol. Cell. Biol.* 10:4239-4242 (1990)). While proliferation of the target cell is readily achieved in vitro, proliferation of many potential target cells in vivo is very low.

Yet another viral candidate useful as an expression vector for transformation of cells is the adenovirus, a double-stranded DNA virus. The adenovirus is frequently responsible for respiratory tract infections in humans and thus appears to have an avidity for the epithelium of the respiratory tract (Straus, S., *The Adenovirus*, H. S. Ginsberg, Editor, Plenum Press, New York, P. 451-496 (1984)). Moreover, the adenovirus is infective in a wide range of cell types, including, for example, muscle and endothelial cells (Larrick, J. W. and Burck, K. L., *Gene Therapy. Application of Molecular Biology*, Elsevier Science Publishing Co., Inc., New York, p. 71-104 (1991)). The adenovirus also has been used as an expression vector in muscle cells in vivo (Quantin, B., et al., *Proc. Natl. Acad. Sci. USA* 89:2581-2584 (1992)).

Like the retrovirus, the adenovirus genome is adaptable for use as an expression vector for gene therapy, i.e., by removing the genetic information that controls production of the virus itself (Rosenfeld, M. A., et al., *Science* 252:431434 (1991)). Because the adenovirus functions in an extrachromosomal fashion, the recombinant adenovirus does not have the theoretical problem of insertional mutagenesis.

Finally, a third virus family adaptable for an expression vector for gene therapy are the recombinant adeno-associated viruses, specifically those based on AAV2, AAV4 and AAV5 (Davidson et al, *PNAS*, 2000)

Thus, as will be apparent to one of ordinary skill in the art, a variety of suitable viral expression vectors are available for transferring exogenous genetic material into cells. The selection of an appropriate expression vector to express a therapeutic agent for a particular condition amenable to gene replacement therapy and the optimization of the conditions for insertion of the selected expression vector into the cell, are within the scope of one of ordinary skill in the art without the need for undue experimentation.

In an alternative embodiment, the expression vector is in the form of a plasmid, which is transferred into the target cells by one of a variety of methods:

physical (e.g., microinjection (Capecchi, M. R., Cell 22:479-488 (1980)),  
electroporation (Andreason, G. L. and Evans, G. A. Biotechniques 6:650-660  
(1988), scrape loading, microparticle bombardment (Johnston, S. A., Nature  
346:776-777 (1990)) or by cellular uptake as a chemical complex (e.g., calcium  
5 or strontium co-precipitation, complexation with lipid, complexation with  
ligand) (Methods in Molecular Biology, Vol. 7, Gene Transfer and Expression  
Protocols, Ed. E. J. Murray, Humana Press (1991)). Several commercial  
products are available for cationic liposome complexation including  
Lipofectin™ (Gibco-BRL, Gaithersburg, Md.) (Felgner, P. L., et al., Proc. Natl.  
10 Acad. Sci. 84:7413-7417 (1987)) and Transfectam™ (ProMega, Madison, Wis.)  
(Behr, J. P., et al., Proc. Natl. Acad. Sci. USA 86:6982-6986 (1989); Loeffler, J.  
P., et al., J. Neurochem. 54:1812-1815 (1990)). However, the efficiency of  
transfection by these methods is highly dependent on the nature of the target cell  
and accordingly, the conditions for optimal transfection of nucleic acids into  
15 cells using the above-mentioned procedures must be optimized. Such  
optimization is within the scope of one of ordinary skill in the art without the  
need for undue experimentation.

The instant invention also provides various methods for making and  
using the above-described genetically-modified cells. In particular, the invention  
20 provides a method for genetically modifying cell(s) of a mammalian recipient ex  
vivo and administering the genetically modified cells to the mammalian  
recipient. In one embodiment for ex vivo gene therapy, the cells are autologous  
cells, i.e., cells isolated from the mammalian recipient. As used herein, the term  
"isolated" means a cell or a plurality of cells that have been removed from their  
25 naturally-occurring in vivo location. Methods for removing cells from a patient,  
as well as methods for maintaining the isolated cells in culture are known to  
those of ordinary skill in the art.

The instant invention also provides methods for genetically modifying  
cells of a mammalian recipient in vivo. According to one embodiment, the  
30 method comprises introducing an expression vector for expressing a  
heterologous gene product into cells of the mammalian recipient in situ by, for  
example, injecting the vector into the recipient.

In one embodiment, the preparation of genetically modified cells  
contains an amount of cells sufficient to deliver a therapeutically effective dose

of the therapeutic agent to the recipient in situ. The determination of a therapeutically effective dose of a specific therapeutic agent for a known condition is within the scope of one of ordinary skill in the art without the need for undue experimentation. Thus, in determining the effective dose, one of  
5 ordinary skill would consider the condition of the patient, the severity of the condition, as well as the results of clinical studies of the specific therapeutic agent being administered.

If the genetically modified cells are not already present in a pharmaceutically acceptable carrier they are placed in such a carrier prior to  
10 administration to the recipient. Such pharmaceutically acceptable carriers include, for example, isotonic saline and other buffers as appropriate to the patient and therapy.

The genetically modified cells are administered by, for example, intraperitoneal injecting or implanting the cells or a graft or capsule containing  
15 the cells in a target cell-compatible site of the recipient. As used herein, "target cell-compatible site" refers to a structure, cavity or fluid of the recipient into which the genetically modified cell(s), cell graft, or encapsulated cell expression system can be implanted, without triggering adverse physiological consequences

More than one recombinant gene can be introduced into each genetically  
20 modified cell on the same or different vectors, thereby allowing the expression of multiple therapeutic agents by a single cell.

The instant invention further embraces a cell graft. The graft comprises a plurality of the above-described genetically modified cells attached to a support that is suitable for implantation into a mammalian recipient. The support can be  
25 formed of a natural or synthetic material.

According to another aspect of the invention, an encapsulated cell expression system is provided. The encapsulated system includes a capsule suitable for implantation into a mammalian recipient and a plurality of the above-described genetically modified cells contained therein. The capsule can  
30 be formed of a synthetic or naturally-occurring material. The formulation of such capsules is known to one of ordinary skill in the art. In contrast to the cells which are directly implanted into the mammalian recipient (i.e., implanted in a manner such that the genetically modified cells are in direct physical contact with the cell-compatible site), the encapsulated cells remain isolated (i.e., not in

direct physical contact with the site) following implantation. Thus, the encapsulated system is not limited to a capsule including genetically-modified non-immortalized cells, but may contain genetically modified immortalized cells.

5           The following provides examples of how the Tat-PTD alters the properties of a representative lysosomal protein,  $\beta$ -glucuronidase. Similar results would be expected for all soluble lysosomal proteins. Moreover, the data would also hold for other non-lysosomal proteins that are normally secreted, or to proteins modified to contain a signal sequence to allow for their secretion. The  
10       underlying theme is that the inclusion of a PTD onto those sequences will allow for altered and improved biodistribution for therapeutic purposes.

          Therefore, the following examples are intended to illustrate but not limit the invention.

### **EXAMPLES**

#### 15       Example 1: Production of Recombinant vectors

          Primer 1 (5'-AAACTCGAGATGGCCCGGGGTCGGCGGTTGCC-3')  
(SEQ ID NO:1) and primer 2 (5'-  
TGCTCTAGATCATCTTCGTCGCTGTCTCCGCTTCTTCCTGCCATAACCG  
CCACCG-CCAGTAAACGGGCTGTT T TCCAAACA-3') (SEQ ID NO:2)  
20       were used to create the  $\beta$ -glucuronidase-Tat<sub>47-57</sub> fusion protein. Primer 1 and  
primer 3 (5'TGCTCTAGATCAATAGCCCCTCTTC TTCCGTCT  
CTGTCGTCGTCTACCGCCACCGCCAGTAAACGGGCTGTTTTCCA  
AACA-3') (SEQ ID NO:3) were used to make the  $\beta$ -glucuronidase-Tat<sub>57-47</sub>  
fusion protein. PCR fragments were digested with *XhoI* and *XbaI* and the  
25       fragments cloned into similarly cut E1 shuttle plasmids (pPacRSVKpnA;  
described in (Anderson, *et al.*, (2000) *Gene Ther.* **7**(12):1034-1038)). The  
resultant plasmids were named pPacRSV $\beta$ Gluc-Tat PTD<sub>47-57</sub> or pPacRSV  
 $\beta$ Gluc-Tat PTD<sub>57-47</sub>. Adenoviruses with  $\beta$ -glucuronidase,  $\beta$ -glucuronidase-Tat  
PTD<sub>47-57</sub> or  $\beta$ -glucuronidase-Tat PTD<sub>57-47</sub> in E1 and eGFP in E3 were produced by  
30       co-transfecting PacI linearized pPacRSV $\beta$ Gluc-Tat PTD<sub>47-57</sub>, pPacRSV $\beta$ Gluc-  
Tat PTD<sub>57-47</sub> or pPacRSV $\beta$ gluc with PacI digested E3 modified Ad5 backbones  
containing a RSVGFP expression cassette in E3. For ease of discussion the  
recombinant viruses, Ad5 $\beta$ gluc-Tat<sub>47-57</sub>/E3GFP, Ad5 $\beta$ gluc-Tat<sub>57-47</sub>/E3GFP or  
Ad5 $\beta$ gluc/E3GFP are listed as Ad $\beta$ gluc-Tat<sub>47-57</sub>, Ad $\beta$ gluc-Tat<sub>57-47</sub> or Ad $\beta$ gluc.

Viruses were purified by CsCl gradient ultracentrifugation. Infectious units were determined by plaque assay and particle titers by OD<sub>260</sub>.

#### Example 2. In vitro studies

5            HeLa cells were infected with Ad $\beta$ gluc-Tat<sub>47-57</sub>, Ad $\beta$ gluc-Tat<sub>57-47</sub> or control Ad $\beta$ gluc at 20 infectious units (i.u.)/cell and supernatants harvested 72 h later.  $\beta$ -Glucuronidase activity was quantified using the previously described fluorometric assay. Briefly, aliquots were reacted in 10 mM 4-methylumbelliferyl- $\beta$ -D-glucuronidase (Sigma, St. Louis, MO) in 0.1 M sodium acetate (pH 4.8) for 1 h at 37 °C. Reactions were stopped by addition of 2 ml of 320 mM glycine in 200 mM carbonate buffer, pH 10.0 (Glaser, *et al.*, (1973) *J.Lab.Clin.Med.* **82**:969-977). Fluorescence was measured at 415nm after excitation at 360nm (TD-700 Fluorometer; Turner Design, Sunnyvale, CA).  $\beta$ -Glucuronidase activity is expressed as nanomoles of 4-methylumbelliferone released per hour (FLU) per mg protein. Purified  $\beta$ -glucuronidase (kindly provided by William Sly, Washington University, St. Louis MO) was used as standard. Protein concentrations were determined using the Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA).

20            NIH 3T3 or A549 cells (500,000 cells plated the day before) were incubated with 5500 units of  $\beta$ -glucuronidase-Tat<sub>47-57</sub>,  $\beta$ -glucuronidase-Tat<sub>57-47</sub> or  $\beta$ -glucuronidase in the presence or absence of D-mannose-6-phosphate (10 mM) for 2 h at 37 or 4 °C. After incubation cells were harvested and lysates prepared for fluorometric enzyme assay, or stained for  $\beta$ -glucuronidase activity *in situ*. For  $\beta$ -glucuronidase staining, cells were washed in PBS, fixed in 2% paraformaldehyde for 15 min, washed twice in PBS, twice with 0.05M sodium acetate, pH 4.5, for 5 min, and then incubated in 0.25 mM Naph-As-Bi- $\beta$ -glucuronide (Sigma) in the same buffer for 40 min. Cells or tissues (below) were then stained for 30 min at 37 °C with 0.25 mM Naph-As-Bi- $\beta$ -glucuronide in 0.05 M sodium acetate, pH 5.2, with 1/500 2% hexazotized pararosaniline (Sigma).

#### Example 3. In vivo studies

$\beta$ -Glucuronidase-deficient mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and from our own breeding colony. The genotype

for the latter was confirmed by morphological and genetic analyses. The animals were between 8 and 10 weeks old and weighed 16-24 g. C57BL/6 wild-type mice were purchased from Harlan Sprague (Indianapolis, IN).

Ad $\beta$ gluc-Tat<sub>47-57</sub>, Ad $\beta$ gluc-Tat<sub>57-47</sub> or Ad $\beta$ gluc were injected into the tail  
5 vein ( $2 \times 10^9$  i.u.) of  $\beta$ -glucuronidase deficient mice. Ad $\beta$ gluc-Tat<sub>47-57</sub>,  
Ad $\beta$ gluc-Tat<sub>57-47</sub> or Ad $\beta$ gluc ( $2 \times 10^7$  i.u. total) were injected into the right  
striatum or right lateral ventricle of C57BL/6 mice or  $\beta$ -glucuronidase deficient  
mice as described earlier (Stein, *et al.*, (1999) *J.Virol.* **73**(4):3424-3429).  
Animals were sacrificed 10 days after intravenous (n=3/group), striatal (n =  
10 5/group) or ventricular injection (n=5/group). Tissues were sonicated, placed in  
lysis solution (Sands, *et al.*, (1994) *J.Clin.Invest.* **93**:2324-2331) and centrifuged  
at 12000 X g for 20 min. Aliquots were assayed using the fluorometric assay  
described above. For *in situ* enzyme assays, tissues were harvested, sectioned,  
and stained *in situ* for  $\beta$ -glucuronidase activity as described above.

15 Coronal brain sections were photographed with Adobe Photoshop  
(Adobe system, Mountain View, CA), and the photos imported into NIH Image.  
Color thresh-holding was used, and the percentage of brain positive for activity  
calculated by dividing the area of staining by the total area (adjusted for  
ventricular size). In all cases a minimum of 2 mm (rostral to caudal) of  
20 cerebrum surrounding the injection site was scanned.

All publications, patents and patent applications are incorporated herein  
by reference. While in the foregoing specification this invention has been  
described in relation to certain embodiments, and many details have been set  
forth for purposes of illustration, it will be apparent to those skilled in the art that  
25 the invention is susceptible to additional embodiments and that certain of the  
details described herein may be varied considerably without departing from the  
basic principles of the invention.



## REFERENCES

1. Meikle, P.J., Hopwood, J.J., Clague, A.E. and Carey, W.F. 1999. Prevalence of lysosomal storage disorders. *JAMA* **281**(3):249-254.
2. O'Connor, L.H., Erway, L.C., Vogler, C.A., Sly, W.S., Nicholes, A., Grubb, J., Holmberg, S.W., Levy, B. and Sands, M.S. 1998. Enzyme replacement therapy for murine mucopolysaccharidosis Type VII leads to improvements in behavior and auditory function. *J.Clin.Invest.* **101**:1394-1400.
3. Frisella, W.A., O'Connor, L.H., Vogler, C.A., Roberts, M., Walkley, S., Levy, B., Daly, T.M. and Sands, M.S. 2001. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. *Mol.Ther.* (In Press)
4. Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L.L., Pepinsky, B. and Barsoum, J. 1994. Tat-mediated delivery of heterologous proteins into cells. *Proc.Natl.Acad.Sci.U.S.A.* **91**:664-668.
5. Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. *Science* **285**:1569-1572.
6. Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G. and Prochiantz, A. 1996. Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. *J.Biol.Chem.* **271**(30):18188-18193.
7. Ghodsi, A., Stein, C., Derksen, T., Yang, G., Anderson, R.D. and Davidson, B.L. 1998. Extensive  $\beta$ -glucuronidase activity in murine CNS after adenovirus mediated gene transfer to brain. *Hum.Gene Ther.* **9**:2331-2340.
8. Mann, D.A. and Frankel, A.D. 1991. Endocytosis and targeting of exogenous HIV-1 tat protein. *EMBO J.* **10**(7):1733-1739.
9. Stein, C.S., Ghodsi, A., Derksen, T. and Davidson, B.L. 1999. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. *J.Virol.* **73**(4):3424-3429.
10. Ghodsi, A., Stein, C., Derksen, T., Martins, I., Anderson, R.D. and Davidson, B.L. 1999. Systemic hyperosmolality improves  $\beta$ -glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. *Exp.Neurol.* **160**:109-116.

11. Davidson, B.L., Stein, C.S., Heth, J.A., Martins, I., Kotin, R.M., Derksen, T.A., Zabner, J., Ghodsi, A. and Chiorini, J.A. 2000. Recombinant AAV type 2, 4 and 5 vectors: transduction of variant cell types and regions in the mammalian CNS. *Proc.Natl.Acad.Sci.U.S.A.* **97(7)**:3428-3432.
- 5        12. Anderson, R.D., Haskell, R.E., Xia, H., Roessler, B.J. and Davidson, B.L. 2000. A simple method for the rapid generation of recombinant adenovirus vectors. *Gene Ther.* **7(12)**:1034-1038.
13. Glaser, J.H. and Sly, W.S. 1973. Beta-glucuronidase deficiency mucopolysaccharidosis: Methods for enzymatic diagnosis. *J.Lab.Clin.Med.*  
10    **82**:969-977.
14. Sands, M.S., Vogler, C., Kyle, J.W., Grubb, J.H., Levy, B., Galvin, N., Sly, W.S. and Birkenmeier, E.H. 1994. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. *J.Clin.Invest.* **93**:2324-2331.

What is claimed is:

1. A polynucleotide comprising a nucleic acid sequence encoding a lysosomal enzyme, a secreted protein, a nuclear protein, or a cytoplasmic protein  
5 operably linked to a nucleic acid sequence encoding a protein transduction domain (PTD).
2. The polynucleotide of claim 1, wherein the nucleic acid sequence encodes a lysosomal enzyme.  
10
3. The polynucleotide of claim 2, wherein the lysosomal enzyme is a soluble lysosomal enzyme.
4. The polynucleotide of claim 3, wherein the soluble lysosomal enzyme is  
15  $\beta$ -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.
5. The polynucleotide of claim 3, wherein the soluble lysosomal enzyme is  $\beta$ -glucuronidase.
- 20 6. The polynucleotide of claim 1, wherein the nucleic acid sequence encodes a secreted protein.
7. The polynucleotide of claim 2, wherein the secreted protein is a growth factor or an anti-neoplastic protein.  
25
8. The polynucleotide of claim 7, wherein the growth factor is GDNF, NGF, BDNF, or NT3.
9. The polynucleotide of claim 7, wherein the anti-neoplastic protein is an  
30 inhibitor of neovascularization, cell migration, or cell proliferation.
10. The polynucleotide of claim 1, wherein the polynucleotide is a nuclear protein.

11. The polynucleotide of claim 10, wherein the nuclear protein is a transcription factor.
12. The polynucleotide of claim 1, wherein the polynucleotide is a cytoplasmic protein.
13. The polynucleotide of claim 12, wherein the cytoplasmic protein is a cytotoxic agent.
14. The polynucleotide of claim 1, wherein the PTD is Tat PTD.
15. The polynucleotide of claim 14, wherein the Tat PTD is Tat<sub>47-57</sub>.
16. An expression vector comprising a nucleic acid sequence encoding a lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a nucleic acid sequence encoding a PTD.
17. The vector of claim 16, wherein the nucleic acid sequence encodes a lysosomal enzyme.
18. The vector of claim 16, wherein the lysosomal enzyme is a soluble lysosomal enzyme.
19. The vector of claim 18, wherein the soluble lysosomal enzyme is  $\beta$  - glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.
20. The vector of claim 19, wherein the soluble lysosomal enzyme is  $\beta$  - glucuronidase
21. The vector of claim 16, wherein the nucleic acid sequence encodes a secreted protein.
22. The vector of claim 21, wherein the secreted protein is a growth factor or an anti-neoplastic protein.

23. The vector of claim 22, wherein the growth factor is GDNF, NGF, BDNF, or NT3.
- 5 24. The vector of claim 22, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.
25. The vector of claim 16, wherein the nucleic acid is a nuclear protein.
- 10 26. The vector of claim 25, wherein the nuclear protein is a transcription factor.
27. The vector of claim 16, wherein the nucleic acid is a cytoplasmic protein.
- 15 28. The vector of claim 27, wherein the cytoplasmic protein is a cytotoxic agent.
29. The vector of claim 16, wherein the PTD is Tat PTD.
- 20 30. The vector of claim 29, wherein the Tat PTD is Tat<sub>47-57</sub>.
31. The vector of claim 16, wherein the vector is an adenoviral vector.
32. The vector of claim 16, wherein the vector is an adeno-associated virus  
25 vector.
33. The vector of claim 16, wherein the vector is a recombinant lentivirus or retrovirus vector.
- 30 34. A polypeptide comprising a lysosomal enzyme, a naturally secreted protein, a nuclear protein, or a cytoplasmic protein operably linked to a nucleic acid sequence encoding a PTD.

35. The polypeptide of claim 34, wherein the polypeptide is a lysosomal enzyme.
36. The polypeptide of claim 34, wherein the lysosomal enzyme is a soluble  
5 lysosomal enzyme.
37. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is  $\beta$ -glucuronidase, pepstatin insensitive protease or palmitoyl protein thioesterase.
- 10 38. The polypeptide of claim 36, wherein the soluble lysosomal enzyme is  $\beta$ -glucuronidase
39. The polypeptide of claim 34, wherein the polypeptide is a secreted  
15 protein.
40. The polypeptide of claim 39, wherein the secreted protein is a growth factor or an anti-neoplastic protein.
41. The polypeptide of claim 40, wherein the growth factor is GDNF, NGF,  
20 BDNF, or NT3.
42. The polypeptide of claim 40, wherein the anti-neoplastic protein is an inhibitor of neovascularization, cell migration, or cell proliferation.
- 25 43. The polypeptide of claim 34, wherein the polypeptide is a nuclear protein.
44. The polypeptide of claim 43, wherein the nuclear protein is a  
transcription factor.
- 30 45. The polypeptide of claim 34, wherein the polypeptide is a cytoplasmic protein.

46. The polypeptide of claim 45, wherein the cytoplasmic protein is a cytotoxic agent.
47. The polypeptide of claim 34, wherein the PTD is Tat PTD.
- 5 48. The polypeptide of claim 47, wherein the Tat PTD is Tat<sub>47-57</sub>.
49. A mammalian cell comprising the vector of claim 12.
- 10 50. The cell of claim 49, wherein the cell is human.
51. The cell of claim 49, wherein the cell is from spleen, kidney, lung, heart, liver or brain.
- 15 52. The cell of claim 49, wherein the cell is a stem or progenitor cell.
53. A method of treating a genetic disease or cancer in a mammal comprising administering the polynucleotide of claim 1.
- 20 54. The method of claim 53, wherein the mammal is human.
55. The method of claim 53, wherein the genetic disease is a lysosomal storage disease (LSD).
- 25 56. The method of claim 55, wherein the LSD is infantile or late infantile ceroid lipofuscinoses, Gaucher, Juvenile Batten, Fabry, MLD, Sanfilippo A, Late Infantile Batten, Hunter, Krabbe, Morquio, Pompe, Niemann-Pick C, Tay-Sachs, Hurler (MPS-I H), Sanfilippo B, Maroteaux-Lamy, Niemann-Pick A, Cystinosis, Hurler-Scheie (MPS-I H/S), Sly Syndrome (MPS VII), Scheie (MPS-
- 30 I S), Infantile Batten, GM1 Gangliosidosis, Mucopolidosis type II/III, or Sandhoff disease.
57. The method of claim 53, wherein the genetic disease is a neurodegenerative disease.

58. The method of claim 57, wherein the neurodegenerative disease is Huntington's disease, ALS, hereditary spastic hemiplegia, primary lateral sclerosis, spinal muscular atrophy, Kennedy's disease, Alzheimer's disease, a  
5 polyglutamine repeat disease, or focal exposure such as Parkinson's disease.

59. A method of treating a genetic disease or cancer in a mammal comprising administering the vector of claim 16.

10 60. A method of treating a genetic disease or cancer in a mammal comprising administering the polypeptide of claim 34.

61. A method of treating a genetic disease or cancer in a mammal comprising administering the cell of claim 49.

15







FIG. 1

2/6




FIG. 2





FIG. 3



4/6




FIG. 4

5/6




FIG. 5

6/6




FIG. 6

## SEQUENCE LISTING

<110> University of Iowa Research Foundation  
Davidson, Beverly

5 Mao, Qinwen  
Xia, Haibin

<120> PTD-Modified Proteins

10<130> 875.043WO1

<150> US 09/757,824

<151> 2001-01-09

15<160> 3

<210> 1

<211> 33

<212> DNA

20<213> Adenovirus

<400> 1

aaactcgaga tggcccgggg gtcggcggtt gcc 33

25<210> 2

<211> 81

<212> DNA

<213> Adenovirus

30<400> 2

tgctctagat catcttcgtc gctgtctccg cttcttcctg ccataaccgc caccgccagt 60

aaacgggctg ttttccaaac a 81

<210> 3

35<211> 81

<212> DNA

<213> Adenovirus

<400> 3

40tgctctagat caatagcccc tcttcttcctg tctctgtcgt cgtctaccgc caccgccagt 60

aaacgggctg ttttccaaac a 81

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number  
**WO 02/055684 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/16**,  
C12N 15/62, A61K 48/00, 38/47

(21) International Application Number: PCT/US02/00438

(22) International Filing Date: 9 January 2002 (09.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/757,824 9 January 2001 (09.01.2001) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF IOWA RESEARCH FOUNDATION**  
[US/US]; Oakdale Research Campus, 100 Oakdale Campus #214 TIC, Iowa City, IA 52242-5000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIDSON, Beverly, L.** [US/US]; 3640 Johnston Way, N.E., North Liberty, IA 52242 (US). **MAO, Qinwen** [CN/US]; 1264 Shannon Drive, Iowa City, IA 52246 (US). **XIA, Haibin** [CN/US]; 1264 Shannon Drive, Iowa City, IA 52246 (US).

(74) Agent: **VIKSINS, Ann, S.**; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).

(81) Designated States (*national*): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(88) Date of publication of the international search report:  
5 June 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYNTHETIC PROTEINS CONTAINING A PROTEIN TRANSDUCTION DOMAIN

$\beta$ -gluc

$\beta$ -glucTat<sub>47-57</sub>



(57) Abstract: The present invention provides polynucleotides and expression vectors containing a sequence encoding a soluble lysosomal enzyme and a sequence encoding Tat protein transduction domain (PTD), and the corresponding polypeptides. The present demonstrates the utility of these protein fusions in altering the bioavailability of proteins for use in treating genetic diseases or acquired diseases. The invention further provides cell expression systems, and methods of treating a genetic disease or cancer in a mammal using the polynucleotides, polypeptides, or expression system of the present invention.

WO 02/055684 A3



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/00438

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/16 C12N15/62 A61K48/00 A61K38/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, EMBASE, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FORD K G ET AL: "PROTEIN TRANSDUCTION: AN ALTERNATIVE TO GENETIC INTERVENTION?" GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 8, no. 1, January 2001 (2001-01), pages 1-4, XP001098109 ISSN: 0969-7128	1,6,7, 9-16,21, 22, 24-30, 34,39, 40, 42-51, 53,54, 57,59-61 1-61
Y	the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

20 March 2003

Date of mailing of the international search report

27/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Wimmer, G

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/00438

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	STEIN C S ET AL: "Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 4, 1999, pages 3424-3429, XP002175115 ISSN: 0022-538X cited in the application the whole document ---	1-61
X	FORD K G ET AL: "Protein transduction: A new tool for the study of cellular ageing and senescence" MECHANISMS OF AGEING AND DEVELOPMENT, ELSEVIER SEQUOIA, LAUSANNE,, CH, vol. 121, no. 1-3, 20 December 2000 (2000-12-20), pages 113-121, XP002222583 ISSN: 0047-6374 the whole document ---	1,6,7, 9-16,21, 22, 24-30, 34,39, 40, 42-51, 53,54, 59-61 1-61
Y	the whole document ---	1-61
X	NAGAHARA H ET AL: "TRANSDUCTION OF FULL-LENGTH TAT FUSION PROTEINS INTO MAMMALIAN CELLS: TAT-P27KIP1 INDUCES CELL MIGRATION" NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 12, December 1998 (1998-12), pages 1449-1452, XP002927987 ISSN: 1078-8956 the whole document ---	1,10, 12-16, 25, 27-30, 34,43, 45-51, 53,54, 59-61
X	WO 00 34308 A (UNIV WASHINGTON) 15 June 2000 (2000-06-15) ---	1,6,7, 9-16,21, 22, 24-30, 34,39, 40, 42-51, 53,54, 59-61
Y	the whole document ---	1-61
X	PHELAN A ET AL: "INTERCELLULAR DELIVERY OF FUNCTIONAL P53 BY THE HERPESVIRUS PROTEINVP22" NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 16, no. 5, May 1998 (1998-05), pages 440-443, XP000979081 ISSN: 1087-0156 the whole document ---	1,10,11, 16,25, 26,34, 43,44, 49-51, 53,54, 59-61
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/00438

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHWARZE S R ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse" SCIENCE, AAAS. LANCASTER, PA, US, vol. 285, 3 September 1999 (1999-09-03), pages 1569-1572, XP002204883 ISSN: 0036-8075 cited in the application the whole document	1,10,12, 14-16, 25,27, 29,30, 34,43, 45, 47-51,60
Y	----- the whole document	1-61
X	MI Z ET AL: "CHARACTERIZATION OF A CLASS OF CATIONIC PEPTIDES ABLE TO FACILITATE EFFICIENT PROTEIN TRANSDUCTION IN VITRO AND IN VIVO" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 2, no. 4, October 2000 (2000-10), pages 339-347, XP000998662 ISSN: 1525-0016 the whole document -----	1,10,12, 16,25, 27,34, 43,45, 49-51, 53,54, 59,60

# INTERNATIONAL SEARCH REPORT

national application No.  
PCT/US 02/00438

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 53-61 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

-----

Continuation of Box I.2

Present claim 34 relates to a polypeptide comprising a protein part "operably linked to a nucleic acid sequence encoding a PTD". Since the present application only discloses fusions of peptides to a peptidic protein transduction domain, it was assumed that this claim was erroneously formulated. Therefore, this search report was established for subject-matter of claim 34 (and dependent claims 35-48) under the assumption that the claims refer to a fusion polypeptide comprising a first protein linked to a protein transduction domain.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 02/00438

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0034308	A	15-06-2000	AU 2172800 A	26-06-2000
			CA 2354044 A1	15-06-2000
			EP 1137664 A2	04-10-2001
			JP 2002531113 T	24-09-2002
			WO 0034308 A2	15-06-2000
-----				